valproic acid has been researched along with Local Neoplasm Recurrence in 19 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We describe a novel ER+ breast cancer model to study de novo and acquired tamoxifen (TAM) resistance." | 7.85 | Effects of In Utero Exposure to Ethinyl Estradiol on Tamoxifen Resistance and Breast Cancer Recurrence in a Preclinical Model. ( Bouker, KB; Clarke, R; Cook, KL; Cruz, MI; de Assis, S; Hilakivi-Clarke, L; Hu, R; Jin, L; Nguyen, N; Wang, X; Wang, Y; Wärri, A; Wehrenberg, B; Xuan, J; Zhang, X; Zwart, A, 2017) |
| "To examine the efficacy of valproic acid (VPA) given either with or without levetiracetam (LEV) on seizure control and on survival in patients with glioblastoma multiforme (GBM) treated with chemoradiation." | 7.79 | Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. ( Dielemans, JC; Kerkhof, M; Taphoorn, MJ; van Breemen, MS; Vecht, CJ; Walchenbach, R; Zwinkels, H, 2013) |
| "Recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) has a poor prognosis and the combination of cisplatin and cetuximab, with or without 5-fluorouracil, is the gold standard treatment in this stage." | 6.82 | Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial. ( Aversa, C; Botti, G; Bruzzese, F; Budillon, A; Calogero, E; Caponigro, F; Cavalcanti, E; D'Aniello, R; Daponte, A; De Cecio, R; De Feo, G; Di Gennaro, E; Di Marzo, M; Ionna, F; Longo, F; Losito, NS; Maglione, MG; Maiolino, P; Montano, M; Muto, P; Pavone, E; Perri, F; Petrillo, A; Pontone, M; Sandomenico, F; Scala, S; Trotta, A; Zotti, AI, 2016) |
| "Valproic acid (VPA) is an anti-epileptic drug with properties of a histone deacetylase inhibitor (HDACi)." | 5.43 | Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide. ( Dietrich, J; Le, A; McDonnell, E; Nahed, BV; Redjal, N; Reinshagen, C; Walcott, BP, 2016) |
| "We describe a novel ER+ breast cancer model to study de novo and acquired tamoxifen (TAM) resistance." | 3.85 | Effects of In Utero Exposure to Ethinyl Estradiol on Tamoxifen Resistance and Breast Cancer Recurrence in a Preclinical Model. ( Bouker, KB; Clarke, R; Cook, KL; Cruz, MI; de Assis, S; Hilakivi-Clarke, L; Hu, R; Jin, L; Nguyen, N; Wang, X; Wang, Y; Wärri, A; Wehrenberg, B; Xuan, J; Zhang, X; Zwart, A, 2017) |
| "To examine the efficacy of valproic acid (VPA) given either with or without levetiracetam (LEV) on seizure control and on survival in patients with glioblastoma multiforme (GBM) treated with chemoradiation." | 3.79 | Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. ( Dielemans, JC; Kerkhof, M; Taphoorn, MJ; van Breemen, MS; Vecht, CJ; Walchenbach, R; Zwinkels, H, 2013) |
| " We have used several models of PML-RARA-driven acute promyelocytic leukemias (APLs) to analyze the in vivo effects of valproic acid, a well-characterized HDACis." | 3.78 | Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL. ( Dal Zuffo, R; de Thé, H; Leiva, M; Mercurio, C; Minucci, S; Moretti, S; Pallavicini, I; Peres, L; Soilihi, H, 2012) |
| "Recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) has a poor prognosis and the combination of cisplatin and cetuximab, with or without 5-fluorouracil, is the gold standard treatment in this stage." | 2.82 | Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial. ( Aversa, C; Botti, G; Bruzzese, F; Budillon, A; Calogero, E; Caponigro, F; Cavalcanti, E; D'Aniello, R; Daponte, A; De Cecio, R; De Feo, G; Di Gennaro, E; Di Marzo, M; Ionna, F; Longo, F; Losito, NS; Maglione, MG; Maiolino, P; Montano, M; Muto, P; Pavone, E; Perri, F; Petrillo, A; Pontone, M; Sandomenico, F; Scala, S; Trotta, A; Zotti, AI, 2016) |
| "Thirty-one elderly AML/RAEB patients (AML n=25; RAEB n=6) with a high rate of comorbidity were entered in a phase II study with low-dose cytarabine (Ara-C) and VPA." | 2.76 | Hematologic improvement and response in elderly AML/RAEB patients treated with valproic acid and low-dose Ara-C. ( Alvaro, MG; Baraldi, A; Ciravegna, G; Corsetti, MT; De Paoli, L; Gatto, S; Levis, A; Perticone, S; Pietrasanta, D; Pini, M; Primon, V; Salvi, F; Tonso, A; Zallio, F, 2011) |
| " This was achieved safely through a reduced dosing schedule of three times a week post dialysis, slow dose titration and blood level monitoring prior to each dialysis session." | 1.62 | Lithium use in a patient on haemodialysis with bipolar affective disorder and lithium-induced nephropathy. ( Salisbury, E; Topp, S, 2021) |
| "Valproic acid (VPA) is an anti-epileptic drug with properties of a histone deacetylase inhibitor (HDACi)." | 1.43 | Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide. ( Dietrich, J; Le, A; McDonnell, E; Nahed, BV; Redjal, N; Reinshagen, C; Walcott, BP, 2016) |
| " Treatment was commenced with the HDACi sodium valproate (VPA) in combination with the anti-viral nucleoside analogue ganciclovir (GCV)." | 1.36 | Sodium valproate in combination with ganciclovir induces lysis of EBV-infected lymphoma cells without impairing EBV-specific T-cell immunity. ( Corbett, G; Gandhi, MK; Jones, K; Nourse, J, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.26) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 14 (73.68) | 24.3611 |
| 2020's | 4 (21.05) | 2.80 |
| Authors | Studies |
|---|---|
| Lai, ZY | 1 |
| Li, DY | 1 |
| Huang, CY | 1 |
| Tung, KC | 1 |
| Yang, CC | 1 |
| Liu, HM | 1 |
| Chou, FI | 1 |
| Chuang, YJ | 1 |
| Zhang, J | 1 |
| Gan, J | 1 |
| Wang, J | 1 |
| Ranjith, S | 1 |
| Abeysundera, H | 1 |
| Jeyaranjan, H | 1 |
| Topp, S | 1 |
| Salisbury, E | 1 |
| Sachkova, A | 1 |
| Sperling, S | 1 |
| Mielke, D | 1 |
| Schatlo, B | 1 |
| Rohde, V | 1 |
| Ninkovic, M | 1 |
| Kerkhof, M | 1 |
| Dielemans, JC | 1 |
| van Breemen, MS | 1 |
| Zwinkels, H | 1 |
| Walchenbach, R | 1 |
| Taphoorn, MJ | 1 |
| Vecht, CJ | 1 |
| Weller, M | 1 |
| Yuan, Y | 1 |
| Xiang, W | 1 |
| Qing, M | 1 |
| Yanhui, L | 1 |
| Jiewen, L | 1 |
| Yunhe, M | 1 |
| Hsu, CL | 1 |
| Kuo, YC | 1 |
| Huang, Y | 1 |
| Huang, YC | 1 |
| Lui, KW | 1 |
| Chang, KP | 1 |
| Lin, TL | 1 |
| Fan, HC | 1 |
| Lin, AC | 1 |
| Hsieh, CH | 1 |
| Lee, LY | 1 |
| Wang, HM | 1 |
| Li, HP | 1 |
| Chang, YS | 1 |
| Redjal, N | 1 |
| Reinshagen, C | 1 |
| Le, A | 1 |
| Walcott, BP | 1 |
| McDonnell, E | 1 |
| Dietrich, J | 1 |
| Nahed, BV | 1 |
| Carter, CA | 1 |
| Zeman, K | 1 |
| Day, RM | 1 |
| Richard, P | 1 |
| Oronsky, A | 1 |
| Oronsky, N | 1 |
| Lybeck, M | 1 |
| Scicinski, J | 1 |
| Oronsky, B | 1 |
| Hilakivi-Clarke, L | 1 |
| Wärri, A | 1 |
| Bouker, KB | 1 |
| Zhang, X | 1 |
| Cook, KL | 1 |
| Jin, L | 1 |
| Zwart, A | 1 |
| Nguyen, N | 1 |
| Hu, R | 1 |
| Cruz, MI | 1 |
| de Assis, S | 1 |
| Wang, X | 1 |
| Xuan, J | 1 |
| Wang, Y | 1 |
| Wehrenberg, B | 1 |
| Clarke, R | 1 |
| Caponigro, F | 1 |
| Di Gennaro, E | 1 |
| Ionna, F | 1 |
| Longo, F | 1 |
| Aversa, C | 1 |
| Pavone, E | 1 |
| Maglione, MG | 1 |
| Di Marzo, M | 1 |
| Muto, P | 1 |
| Cavalcanti, E | 1 |
| Petrillo, A | 1 |
| Sandomenico, F | 1 |
| Maiolino, P | 1 |
| D'Aniello, R | 1 |
| Botti, G | 1 |
| De Cecio, R | 1 |
| Losito, NS | 1 |
| Scala, S | 1 |
| Trotta, A | 1 |
| Zotti, AI | 1 |
| Bruzzese, F | 1 |
| Daponte, A | 1 |
| Calogero, E | 1 |
| Montano, M | 1 |
| Pontone, M | 1 |
| De Feo, G | 1 |
| Perri, F | 1 |
| Budillon, A | 1 |
| Jones, K | 1 |
| Nourse, J | 1 |
| Corbett, G | 1 |
| Gandhi, MK | 1 |
| Rokes, CA | 1 |
| Remke, M | 1 |
| Guha-Thakurta, N | 1 |
| Witt, O | 1 |
| Korshunov, A | 1 |
| Pfister, S | 1 |
| Wolff, JE | 1 |
| Corsetti, MT | 1 |
| Salvi, F | 1 |
| Perticone, S | 1 |
| Baraldi, A | 1 |
| De Paoli, L | 1 |
| Gatto, S | 1 |
| Pietrasanta, D | 1 |
| Pini, M | 1 |
| Primon, V | 1 |
| Zallio, F | 1 |
| Tonso, A | 1 |
| Alvaro, MG | 1 |
| Ciravegna, G | 1 |
| Levis, A | 1 |
| Kuendgen, A | 1 |
| Leiva, M | 1 |
| Moretti, S | 1 |
| Soilihi, H | 1 |
| Pallavicini, I | 1 |
| Peres, L | 1 |
| Mercurio, C | 1 |
| Dal Zuffo, R | 1 |
| Minucci, S | 1 |
| de Thé, H | 1 |
| Matsuda, S | 1 |
| Takahashi, N | 1 |
| Kuwabara, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Prospective Trial for Validation of the Role of Levetiracetam as a Sensitizer of Temozolomide in the Treatment of Newly Diagnosed Glioblastoma Patients[NCT02815410] | Phase 2 | 73 participants (Anticipated) | Interventional | 2016-07-31 | Not yet recruiting | ||
| Phase I Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma[NCT02761291] | Phase 1 | 18 participants (Anticipated) | Interventional | 2016-05-31 | Recruiting | ||
| Preclinical and Clinical Study of Valproic Acid Plus Cisplatin and Cetuximab in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck[NCT02624128] | Phase 2 | 39 participants (Anticipated) | Interventional | 2015-02-23 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for valproic acid and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Survival analysis for valproic acid use in adult glioblastoma multiforme: a meta-analysis of individual patient data and a systematic review.
Topics: Adult; Brain Neoplasms; Glioblastoma; Humans; Neoplasm Recurrence, Local; Survival Analysis; Treatme | 2014 |
Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies.
Topics: Antibodies, Monoclonal; Azacitidine; Azetidines; Benzamides; Biomarkers, Tumor; Carcinoma, Non-Small | 2016 |
2 trials available for valproic acid and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetu | 2016 |
Hematologic improvement and response in elderly AML/RAEB patients treated with valproic acid and low-dose Ara-C.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Anticonvulsants; Antimetabolites | 2011 |
15 other studies available for valproic acid and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Valproic Acid Enhances Radiosensitization
Topics: Animals; DNA; DNA Breaks, Double-Stranded; Humans; Melanoma; Mice; Neoplasm Recurrence, Local; Neutr | 2022 |
A case of GFAP-IgG positivity followed by anti-NMDAR encephalitis.
Topics: Acyclovir; Anti-Inflammatory Agents; Anti-N-Methyl-D-Aspartate Receptor Encephalitis; Autoantibodies | 2022 |
Unusual case of sodium valproate-induced hyperammonaemia encephalopathy.
Topics: Bipolar Disorder; Brain Diseases; Humans; Hyperammonemia; Male; Middle Aged; Neoplasm Recurrence, Lo | 2023 |
Lithium use in a patient on haemodialysis with bipolar affective disorder and lithium-induced nephropathy.
Topics: Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Humans; Kidney Diseases; | 2021 |
Combined Applications of Repurposed Drugs and Their Detrimental Effects on Glioblastoma Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cel | 2019 |
Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 2013 |
Are we ready for a randomized trial of valproic acid in newly diagnosed glioblastoma?
Topics: Anticonvulsants; Brain Neoplasms; Female; Glioblastoma; Humans; Levetiracetam; Male; Neoplasm Recurr | 2013 |
Application of a patient-derived xenograft model in cytolytic viral activation therapy for nasopharyngeal carcinoma.
Topics: Animals; Anticonvulsants; Antimetabolites, Antineoplastic; Antiviral Agents; Apoptosis; Carcinoma; C | 2015 |
Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Agents, Alkylating; Brai | 2016 |
Effects of In Utero Exposure to Ethinyl Estradiol on Tamoxifen Resistance and Breast Cancer Recurrence in a Preclinical Model.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Adenovirus E1A Proteins; Animals; Antineoplastic Combined Chemothe | 2017 |
Sodium valproate in combination with ganciclovir induces lysis of EBV-infected lymphoma cells without impairing EBV-specific T-cell immunity.
Topics: Antiviral Agents; Epstein-Barr Virus Infections; Fatal Outcome; Ganciclovir; Histone Deacetylase Inh | 2010 |
Sorafenib plus valproic acid for infant spinal glioblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Combined Modality Therapy; Extrac | 2010 |
An inexpensive way to treat elderly patients with high-risk MDS or AML.
Topics: Anemia, Refractory, with Excess of Blasts; Anticonvulsants; Antimetabolites, Antineoplastic; Cytarab | 2011 |
Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL.
Topics: Acetylation; Animals; Anticonvulsants; Antineoplastic Agents; Cell Differentiation; Cell Transformat | 2012 |
[A case of Isaacs' syndrome preceding the recurrence of malignant thymoma--generating site of ectopic activity and therapy].
Topics: Anticonvulsants; Electromyography; Fasciculation; Fatal Outcome; Humans; Male; Middle Aged; Neoplasm | 1997 |